1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Circulating tumor cell (CTC) number as a response endpoint in metastatic castration resistant (mCRPC) compared with PSA across five randomized phase 3 trials
    Meeting Abstract

    Heller, G.; McCornnack, R. T.; Kheoh, T.; Smith, M. R.; Dreicer, R.; Saad, F.; De Wit, R.; Aftab, D. T.; Hirmand, M.; MacLean, D. B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Clinical impact of visceral thrombosis (VT) in pancreatic ductal adenocarcinoma (PDAC)
    Meeting Abstract

    Hicks, A. M.; Raj, M.; Do, R. K. G.; Yu, K. H.; Lowery, M. A.; Varghese, A. M.; O'Reilly, E. M.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010
    Meeting Abstract

    Hellmann, M. D.; Ma, J.; Garon, E. B.; Hui, R.; Gandhi, L.; Soria, J. C.; Anderson, K. M.; Lubiniecki, G. M.; Piperdi, B.; Herbst, R. S.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Preliminary results from a single-arm, phase II study assessing the efficacy of pembrolizumab plus radiotherapy in metastatic triple negative breast cancer
    Meeting Abstract

    Ho, A.; Barker, C. A.; Gucalp, A.; Lebron-Zapata, L.; Wen, Y. H.; Phung, A.; Wilgucki, M.; Henrich, M.; Arnold, B.; Patil, S.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Clinicopathologic characteristics of endometrial carcinoma metastatic to the ovary compared to endometrial carcinoma with synchronous ovarian carcinoma
    Meeting Abstract

    Rodriguez Gomez Hidalgo, N.; Soslow, R. A.; Weigelt, B.; Sioulas, V.; Aloisi, A.; Abu-Rustum, N.; Mueller, J. J.; Makker, V.; Leitao, M. M.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase I study of mFOLFOX6 and ADI-PEG-20 in patients (pts) with advanced hepatocellular carcinoma (HCC) and other gastrointestinal (GI) malignancies
    Meeting Abstract

    Harding, J. J.; Lowery, M. A.; Uhlitskykh, K.; Wan, P. J.; Hamilton, C. R.; Barba, A.; Liu, K. C. W.; Johnston, A.; Bomalaski, J. S.; O'Reilly, E. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • HSD3B1 genotype and response to androgen deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer
    Meeting Abstract

    Hearn, J. W. D.; Xie, W.; Nakabayashi, M.; Almassi, N.; Reichard, C. A.; Pomerantz, M.; Kantoff, P. W.; Sharifi, N.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • RASA1 and NF1 co-mutated non-small cell lung carcinomas: Cancer genomic data and evaluation of sensitivity to MEK inhibition
    Meeting Abstract

    Hayashi, T.; Desmeules, P.; Smith, R.; Drilon, A. E.; Somwar, R.; Ladanyi, M.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase 1b study with PEGylated human IL-10 (AM0010) with 5-FU and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC)
    Meeting Abstract

    Hecht, J. R.; Naing, A.; Falchook, G.; Patel, M. R.; Infante, J. R.; Aljumaily, R.; Wong, D. J. L.; Autio, K. A.; Wainberg, Z. A.; Javle, M. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate
    Meeting Abstract

    Hansen, A. R.; Shapiro, G.; Do, K. T.; Kumar, R.; Martin-Liberal, J.; Higano, C. S.; Wisinski, K. B.; Dean, E. J.; Heath, E. I.; Rathkopf, D. E.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save